• Valentina N Nikolić, Milan Stefanović, Dejan Mitić, Slavica Sunarić, Maša Jović, Hristina Trajković, Sanja Stanković, Aleksandra Ignjatović, and Dragana Stokanović.
• Valentina N. Nikolić, Department of Pharmacology with Toxicology, University of Niš Faculty of Medicine, Bul. dr Zorana Djindjica 81, Niš, 18000 Serbia, valentina.nikolic@medfak.ni.ac.rs.
• Croat. Med. J. 2024 Apr 30; 65 (2): 138145138-145.

AimTo investigate the factors affecting metformin concentrations after chronic administration in patients with polycystic ovary syndrome (PCOS), focusing on the pharmacokinetic variability and its implications for personalized therapy.MethodsThis study enrolled 53 PCOS patients undergoing long-term metformin treatment at the Clinic for Gynecology and Obstetrics in Niš, Serbia, from February to December 2019. Pharmacokinetic parameters were measured from blood samples, and metformin concentrations were determined with validated analytical techniques.ResultsThere was a significant variability in metformin concentrations among PCOS patients, with body mass index (BMI) identified as a major influencing factor. Higher BMI was associated with lower plasma metformin levels, a finding suggesting an altered pharmacokinetic profile in obese patients.ConclusionsThis study highlights the critical role of BMI in influencing metformin pharmacokinetics in PCOS patients and underscores the need for personalized treatment strategies in patients with PCOS.

19 keywords...

hide…